Back to top
more

AngioDynamics (ANGO)

(Delayed Data from NSDQ)

$6.99 USD

6.99
415,073

+0.25 (3.71%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $6.99 0.00 (0.00%) 6:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks News

AngioDynamics (ANGO) Q4 Earnings Match Estimates

AngioDynamics (ANGO) delivered earnings and revenue surprises of 0% and 5.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain AngioDynamics (ANGO) Stock Now

AngioDynamics (ANGO) continues to benefit from strength in segments, but forex remains a woe.

AngioDynamics (ANGO) Q3 Earnings Top Estimates, Revenues Lag

AngioDynamics (ANGO) registers strong revenue growth in its Med Tech business as well as domestic revenues in third-quarter fiscal 2022.

Aspira (AWH) Reports Q4 Loss, Lags Revenue Estimates

Aspira (AWH) delivered earnings and revenue surprises of 11.11% and 2.58%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for March 8th

ANGO, BURL, and CABGY have been added to the Zacks Rank #5 (Strong Sell) List on March 8, 2022.

Stereotaxis Inc. (STXS) Reports Q4 Loss, Tops Revenue Estimates

Stereotaxis Inc. (STXS) delivered earnings and revenue surprises of -25% and 1.73%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AngioDynamics (ANGO) Q2 Earnings Lag Estimates, Revenues Top

AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs, as well as in domestic and international revenues in fiscal 2022 Q2.

Analysts Estimate AngioDynamics (ANGO) to Report a Decline in Earnings: What to Look Out for

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neogen (NEOG) Q2 Earnings Miss Estimates

Neogen (NEOG) delivered earnings and revenue surprises of -41.18% and 1.10%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?

HEXO (HEXO) Reports Q1 Loss, Lags Revenue Estimates

HEXO (HEXO) delivered earnings and revenue surprises of 10% and 12.36%, respectively, for the quarter ended October 2021. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.

OPKO Health's (OPK) Arm Declares Readiness for COVID-19 Testing

OPKO Health's (OPK) BioReference Laboratories announces preparedness with respect to COVID-19 testing in the advent of the Omicron Variant.

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woe persists.

Urmimala Biswas headshot

Quest Diagnostics' (DGX) COVID-19 Testing Demand Up in 3 Weeks

According to Quest Diagnostics (DGX), as the nation is entering the holiday season, the importance of testing service is gaining more importance with regard to minimizing the risk of community exposure of COVID-19.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

Cooper Companies' (COO) fiscal fourth-quarter results are likely to reflect segmental strength.

What's in Store for Patterson Companies' (PDCO) Q2 Earnings?

Patterson Companies' (PDCO) fiscal second-quarter results are likely to reflect improvement at Dental segment.

Veeva Systems (VEEV) to Post Q3 Earnings: What's in Store?

Veeva Systems' (VEEV) fiscal third-quarter results are likely to reflect solid show by its segments and robust product portfolio.

Here's Why You Should Retain Patterson Companies (PDCO) Stock

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

PacBio's (PACB) Collaboration to Boost Rare Disease Diagnosis

PacBio's (PACB) recent partnership with ARUP Laboratories, with regard to a study, has the potential to enhance rare disease diagnosis.

Cardinal Health's (CAH) Arm Unveils Supply Automation Solution

Cardinal Health's (CAH) business introduces new offering for clinical labs that can enable them to focus on patient care.

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

PacBio's (PACB) New Solution to Boost Public Health Protection

PacBio's (PACB) newly launched end-to-end solution is likely to help in the fight against infectious diseases and bolster public health response to pathogen threats.

Veeva Systems (VEEV) Vault Quality Suite Gets Adopted by CBM

Veeva Systems' (VEEV) product gets adopted by CBM. This can drive the development and delivery of groundbreaking treatments for patients.

Baxter's (BAX) $100M Investment to Strengthen Global Presence

Baxter's (BAX) strategic investment to help expand the manufacturing footprint of BPS and ensure improvement in products.

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.